Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo‐like kinase inhibitor. The primary endpoints were the maximum tolerated dose of volasertib and the incidence of do...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer Sci
मुख्य लेखकों: Kobayashi, Yukio, Yamauchi, Takahiro, Kiyoi, Hitoshi, Sakura, Toru, Hata, Tomoko, Ando, Kiyoshi, Watabe, Aiko, Harada, Akiko, Taube, Tillmann, Miyazaki, Yasushi, Naoe, Tomoki
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2015
विषय:
Original Articles
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4714695/
https://ncbi.nlm.nih.gov/pubmed/26471242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12814
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन